Hamburg, Germany, and Kyiv, Ukraine — August 14th, 2024 — iniuva GmbH, a Hamburg-based pioneering biotech startup specializing in AI-powered drug discovery, and Enamine Ltd, a Kyiv-based leading provider of chemical compounds and related services, today announced a collaborative research and development program.
The collaboration aims to revolutionize the efficiency and precision of small-molecule drug discovery, particularly in the realm of orphan drugs and pharmacological chaperones. By integrating Enamine’s extensive in-stock and REAL® chemical libraries, compound synthesis and medicinal chemistry expertise with iniuva’s cutting-edge AI platform and disease specific assay models, the partnership is poised to significantly shorten drug development timelines, reduce costs, and enhance the overall drug discovery process. iniuva’s AI platform leverages a feedback-driven process to set new industry standards in model precision, cutting drug development times from years to months and improving drug quality and cost efficiency.
Protein misfolding is a critical mechanism in hundreds of rare diseases, and our AI-driven approach offers unparalleled scalability in targeting these conditions,
said Professor Søren W. Gersting, CEO of iniuva. This collaboration with Enamine will not only expedite the development of effective treatments but also demonstrate the transformative potential of high-quality data and AI integration across the pharmaceutical value chain.
Enamine is excited to partner with iniuva in this groundbreaking project,
said Dr. Vladimir Ivanov, Executive Vice President at Enamine. Our combined expertise will enhance the discovery and development of new small-molecule drugs, demonstrating the critical importance of having the best access to novel and REAL® chemical space through high-quality chemical libraries and laboratory data in creating superior AI models. We hope to be supportive, especially to children with rare genetic disorders for which no cure has been found to date saving and improving their young lives.
This collaboration exemplifies the potential for synergistic partnerships to advance technological innovations and expedite the discovery of potent new drugs. By working together, iniuva and Enamine aim to lead the industry in demonstrating the value of high-quality data and AI in drug discovery, ultimately delivering rapid and effective therapeutic solutions to patients with rare genetic diseases. This collaboration will contribute to ensure that patients with rare diseases can be helped faster and better, thereby improving the lives of many of those affected.